Mark J. Gergen
2023 - Poseida Therapeutics
In 2023, Mark J. Gergen earned a total compensation of $3.8M as Chief Executive Officer, President and Chairman at Poseida Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $336,420 |
|---|---|
| Option Awards | $1,413,936 |
| Salary | $611,667 |
| Stock Awards | $1,442,285 |
| Other | $13,710 |
| Total | $3,818,018 |
Gergen received $1.4M in stock awards, accounting for 38% of the total pay in 2023.
Gergen also received $336.4K in non-equity incentive plan, $1.4M in option awards, $611.7K in salary and $13.7K in other compensation.
Rankings
In 2023, Mark J. Gergen's compensation ranked 186th out of 2,238 executives tracked by ExecPay. In other words, Gergen earned more than 91.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 186 out of 2,238 | 92nd |
Division Manufacturing | 99 out of 1,216 | 92nd |
Major group Chemicals And Allied Products | 64 out of 683 | 91st |
Industry group Drugs | 63 out of 654 | 90th |
Industry Biological Products, Except Diagnostic Substances | 21 out of 160 | 87th |
Source: SEC filing on April 25, 2024.
Gergen's colleagues
We found two more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2023.